Pharma BD Deal Intelligence
The Biovitrum merger built Sobi into a durable European rare disease specialist—$493M in cash and shares consolidating hemophilia, inflammation, and genetic disease assets—though the combined company grew steadily rather than achieving transformative scale.
Focused rare disease merger built Sobi into a viable specialty biopharma
Full analysis, sources & comparables →Biovitrum AB acquired Swedish Orphan International Holding AB for approximately SEK 1.9 billion ($493M) in cash and shares, creating Swedish Orphan Biovitrum (Sobi), a leading European rare disease company focused on hemophilia, inflammation, and genetic diseases.
$3.0B Global Rare Disease Market (~2001)
Biovitrum was spun off from Pharmacia in 2001 with a focus on metabolic diseases, protein drug development, and plasma products. It later merged with Swedish Orphan International in 2010 to form Swedish Orphan Biovitrum (Sobi), a leading rare disease company focused on haemophilia, immunology, and specialty care.
Biovitrum's 2001 spinoff from Pharmacia and subsequent 2010 merger with Swedish Orphan created Sobi, now a major rare disease company with products including Elocta/Alprolix (haemophilia), Kineret (autoinflammatory), and Doptelet (thrombocytopenia). Sobi was acquired by Advent International in 2022 for ~$8B.
Swedish Orphan Biovitrum closes acquisition/merger of Biovitrum for $493M, establishing strategic position and initiating integration.
The Biovitrum merger created Sobi with a focused rare disease strategy that grew steadily but never achieved transformative scale.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Biovitrum (this deal) | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / Innate Pharma SA | 2026 | $580M | 68 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2001 deals · Swedish Orphan Biovitrum AB deals · Hematology deals